articl
summari
similar
replic
kinet
sarscov
demonstr
signific
sensit
type
interferon
treatment
abstract
novel
coronaviru
cov
recent
emerg
caus
ongo
outbreak
viral
pneumonia
around
world
genet
distinct
origin
sarscov
group
cov
share
similar
genom
organ
origin
coronavirus
harbor
bat
importantli
initi
guidanc
use
insight
sarscov
infect
inform
treatment
public
health
strategi
report
evalu
typei
interferon
ifni
sensit
rel
origin
sarscov
result
indic
maintain
similar
viral
replic
kinet
sarscov
vero
cell
novel
cov
much
sensit
ifni
pretreat
examin
transcript
factor
activ
interferon
stimul
gene
isg
induct
context
type
ifn
induc
phosphoryl
increas
isg
protein
contrast
origin
cov
evid
phosphoryl
isg
protein
increas
even
presenc
type
ifn
pretreat
next
examin
ifn
compet
cell
find
reduc
viral
replic
rel
sarscov
induc
phosphoryl
late
infect
final
examin
homolog
sarscov
viral
protein
shown
interferon
antagonist
absenc
open
read
frame
orf
signific
chang
suggest
two
key
ifn
antagonist
may
maintain
equival
function
togeth
result
identifi
key
differ
suscept
ifni
respons
sarscov
could
help
inform
diseas
progress
treatment
option
anim
model
develop
ongo
outbreak
diseas
differ
origin
sarscov
could
leverag
inform
diseas
progress
eventu
treatment
option
addit
find
could
key
implic
anim
model
develop
well
research
modul
type
ifn
respons
earli
infect
end
cluster
patient
hubei
provinc
china
diagnos
viral
pneumonia
unknown
origin
commun
link
hunnan
seafood
market
wuhan
diseas
cluster
echo
sever
acut
respiratori
syndrom
coronaviru
sarscov
outbreak
emerg
begin
centuri
etiolog
agent
identifi
novel
coronaviru
subsequ
renam
new
viru
nearli
nucleotid
ident
origin
sarscov
correspond
cov
diseas
mani
hallmark
sarscov
diseas
includ
fever
breath
difficulti
bilater
lung
infiltr
death
extrem
case
addit
sever
diseas
correspond
old
age
year
old
health
statu
health
care
worker
similar
sar
togeth
result
indic
infect
diseas
strong
similar
origin
sarscov
epidem
occur
nearli
two
decad
earlier
wake
outbreak
major
research
effort
sought
rapidli
character
novel
cov
aid
treatment
control
initi
model
studi
predict
subsequ
cell
cultur
studi
confirm
spike
protein
util
human
angiotensin
convert
enzym
entri
receptor
extens
case
studi
indic
similar
rang
diseas
onset
sever
symptom
seen
sarscov
notabl
less
sever
case
also
observ
captur
origin
sarscov
outbreak
importantli
screen
treatment
guidanc
reli
previou
cov
data
gener
sarscov
merscov
major
antigen
determin
togeth
similar
sarscov
use
respond
newest
cov
outbreak
host
innat
immun
respons
initi
viral
product
recogn
host
cell
pattern
recognit
receptor
includ
tolllik
receptor
tlr
rigilik
receptor
rlr
respons
ultim
result
product
ifni
cytokin
togeth
essenti
effect
antivir
respons
ifni
trigger
signal
cascad
via
receptor
autocrin
paracrin
manner
induc
phosphoryl
signal
transduc
activ
transcript
togeth
third
transcript
factor
form
interferon
stimul
gene
factor
complex
essenti
induct
mani
ifnstimul
gene
isg
ultim
effect
antivir
respons
establish
product
replic
virus
develop
differ
mechan
escap
antivir
respons
target
differ
part
ifni
respons
machineri
studi
character
compar
origin
cov
use
vero
cell
demonstr
maintain
similar
viral
replic
kinet
sarscov
follow
low
dose
infect
contrast
find
much
sensit
ifni
pretreat
compar
sarscov
examin
determin
induc
phosphoryl
isg
express
absent
sarscov
similarli
infect
ifn
compet
cell
result
reduc
replic
phosphoryl
late
time
result
suggest
distinct
chang
cov
term
ifn
antagon
subsequ
examin
sequenc
homolog
sarscov
viral
protein
may
respons
differ
togeth
result
suggest
lack
capac
control
ifni
respons
sarscov
initi
studi
infect
vero
cell
use
low
multipl
infect
moi
explor
viral
replic
kinet
rel
sarscov
follow
infect
find
sarscov
replic
similar
kinet
peak
hour
post
infect
fig
titer
slightli
lower
viral
titer
hour
post
infect
result
statist
differ
novel
cov
origin
epidem
strain
hour
replic
virus
plateau
signific
cytopath
effect
cpe
observ
sarscov
infect
togeth
result
indic
sarscov
replic
similar
replic
kinet
vero
next
evalu
suscept
ifni
pretreat
treatment
ifni
recombin
attempt
antivir
approach
wide
varieti
pathogen
includ
hepat
b
c
virus
well
hiv
sar
merscov
outbreak
ifni
employ
limit
effect
studi
pretreat
vero
cell
unit
recombin
ifni
hour
prior
infect
vero
lack
capac
produc
ifni
abl
respond
exogen
treatment
follow
pretreat
ifni
sarscov
infect
modest
reduct
viral
titer
log
plaqu
form
unit
pfu
compar
untreat
control
hour
post
infect
fig
howev
hour
sarscov
nearli
equival
viral
yield
untreat
condit
log
pfu
versu
log
pfu
contrast
show
signific
reduct
viral
replic
follow
ifni
treatment
hour
post
infect
massiv
hpi
hpi
drop
viral
titer
compar
control
untreat
cell
final
examin
viral
protein
product
find
major
deficit
nucleocapsid
protein
product
ifni
treat
cell
follow
infect
fig
contrast
viral
protein
robustli
express
untreat
cell
sarscov
condit
togeth
result
demonstr
clear
sensit
prime
ifni
respons
observ
sarscov
fail
attenu
phosphoryl
isg
product
explor
differ
ifni
antagon
sarscov
sarscov
examin
activ
ifn
stimul
gene
isg
express
follow
ifn
pretreat
infect
examin
vero
cell
protein
lysat
found
ifni
treat
cell
infect
induc
phosphoryl
hour
post
infect
fig
phosphoryl
absent
untreat
cell
infect
suggest
novel
cov
unabl
inhibit
ifni
preprim
respons
contrast
sarscov
evid
phosphoryl
either
ifni
treat
untreat
cell
illustr
robust
control
ifni
induct
pathway
examin
known
isg
increas
protein
express
context
infect
follow
ifn
pretreat
fig
basal
level
reduc
sarscov
infect
rel
control
like
due
mrna
target
activ
structur
protein
howev
ifni
treatment
result
augment
protein
level
isg
follow
infect
compar
untreat
control
contrast
ifn
treat
sarscov
signific
increas
isg
protein
rel
control
infect
togeth
phosphoryl
isg
product
viral
protein
level
indic
lack
capac
modul
prime
type
ifn
respons
origin
capabl
respond
exogen
type
ifn
vero
cell
lack
capac
produc
type
ifn
follow
infect
like
play
role
robust
replic
wide
rang
virus
evalu
type
ifn
respons
cell
type
infect
cell
lung
epitheli
cell
line
sort
express
previous
use
coronaviru
influenza
research
use
moi
examin
viral
replic
kinet
rel
sarscov
cell
found
sarscov
replic
similar
overal
kinet
peak
hour
post
infect
fig
howev
replic
slightli
attenu
rel
sarscov
hour
post
infect
log
reduct
attenu
viral
replic
expand
hour
log
reduct
indic
signific
chang
total
viral
titer
sarscov
notabl
similar
attenu
observ
untreat
vero
cell
fig
suggest
possibl
immun
modul
infect
evalu
type
ifn
induct
examin
phosphoryl
isg
express
follow
infect
cell
hour
examin
cell
protein
lysat
found
cell
infect
induc
phosphoryl
hour
post
infect
fig
result
correspond
type
ifn
treat
vero
cell
find
fig
suggest
novel
cov
unabl
complet
inhibit
ifni
respons
contrast
sarscov
evid
phosphoryl
cell
illustr
robust
control
ifni
induct
pathway
similar
vero
ifn
pretreat
augment
level
total
observ
rel
sarscov
although
dramat
increas
similarli
found
reduc
sarscov
indic
virus
disrupt
host
protein
product
like
due
mrna
antagon
cov
overal
data
cell
confirm
unabl
maintain
similar
control
ifni
respons
sarscov
consid
sensit
ifni
next
sought
evalu
chang
sarscov
viral
protein
previou
work
establish
sever
key
ifn
antagonist
sarscov
genom
includ
other
therefor
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
compar
sequenc
homolog
across
viral
protein
sarscov
sever
bat
sarslik
virus
includ
use
sequenc
analysi
found
sever
chang
potenti
contribut
type
ifn
sensit
fig
five
survey
group
cov
maintain
howev
homolog
sarscov
three
group
bat
cov
conserv
importantli
two
amino
acid
truncat
previou
work
found
alanin
substitut
ctermin
sarscov
result
ablat
antagon
togeth
sequenc
homolog
analysi
suggest
differ
andor
may
key
driver
type
ifn
suscept
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
ongo
outbreak
caus
viral
character
remain
key
factor
respond
emerg
novel
viru
report
describ
differ
sensit
ifni
indic
distinct
sarscov
suggest
differenti
host
innat
immun
modul
virus
loss
truncationchang
could
signal
reduc
capac
interfer
type
ifn
respons
sarscov
ntermin
domain
shown
clear
role
abil
disrupt
karyopherin
transport
turn
loss
function
would
like
render
much
suscept
ifni
pretreat
activ
capac
enter
nucleu
induc
isg
antivir
respons
studi
found
follow
ifni
pretreat
phosphoryl
induc
follow
infect
increas
isg
protein
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
suggest
effect
block
nuclear
transport
well
sar
sarscov
viral
protein
shown
disrupt
phosphoryl
key
transcript
factor
induct
ifni
antivir
state
mechan
action
clear
absenc
infect
like
impact
abil
inhibit
ifni
respons
eventu
activ
similarli
deubiquitin
domain
remain
intact
aa
insert
upstream
deubiquitin
domain
could
potenti
alter
function
antagonist
maintain
high
level
conserv
singl
point
mutat
key
locat
could
modifi
function
contribut
increas
ifn
sensit
overal
sequenc
analysi
suggest
differ
sarscov
viral
protein
may
drive
attenu
context
type
ifn
pretreat
increas
sensit
suggest
util
treatment
use
type
ifn
ifni
use
respons
chronic
viral
infect
previou
examin
sarscov
case
found
inconclus
effect
type
ifn
treatment
howev
find
sarscov
outbreak
complic
combin
therapi
type
ifn
treatment
includ
ribavirinsteroid
lack
regiment
protocol
type
ifn
util
treat
merscov
infect
patient
conclus
data
yet
exist
determin
efficaci
yet
vivo
studi
merscov
found
earli
induct
type
ifn
protect
mice
importantli
studi
found
late
type
ifn
induct
detriment
merscov
diseas
similarli
earli
report
describ
treatment
use
type
ifn
combin
infect
yet
efficaci
treatment
paramet
use
known
overal
sensit
data
suggest
type
ifn
treatment
may
util
treat
appropri
paramet
determin
addit
use
type
iii
ifn
predict
util
respiratori
tract
could
offer
anoth
mean
effect
treatment
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
addit
treatment
sensit
type
ifn
may
also
implic
anim
model
develop
sarscov
mous
model
recapitul
human
diseas
develop
viru
passag
immun
compet
mice
similarli
mous
model
merscov
requir
adapt
mice
genet
modif
dipeptidylpeptidas
receptor
howev
merscov
mous
model
still
retain
full
immun
capac
contrast
sensit
type
ifn
may
signal
need
use
immun
defici
model
develop
relev
diseas
initi
work
suggest
incompat
infect
mice
base
receptor
usag
type
ifn
respons
may
second
major
barrier
need
overcom
similar
emerg
zika
viru
outbreak
use
type
ifn
receptor
knockout
mice
type
ifn
receptor
block
antibodi
may
necessari
develop
use
anim
model
therapeut
test
overal
result
indic
much
higher
sensit
type
ifn
previous
emerg
sarscov
augment
type
ifn
sensit
like
due
chang
viral
protein
two
epidem
cov
strain
move
forward
data
could
provid
import
insight
treatment
well
develop
novel
anim
model
diseas
ongo
outbreak
result
also
highlight
distinct
highli
relat
virus
suggest
insight
sarscov
must
verifi
infect
diseas
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
virus
cell
provid
world
refer
center
emerg
virus
arbovirus
wrceva
origin
obtain
usa
center
diseas
control
describ
copyright
holder
preprint
peerreview
http
degre
genet
similar
sarscov
across
select
group
coronavirus
viral
host
protein
analysi
evalu
previous
describ
briefli
cell
lysat
resolv
miniprotean
tgx
sdspage
gel
transfer
polyvinyliden
difluorid
pvdf
membran
use
transblot
turbo
transfer
system
membran
block
wv
nonfat
dri
milk
tbst
tb
vv
hr
probe
indic
primari
antibodi
wv
bsa
tbst
overnight
follow
overnight
incub
membran
probe
follow
secondari
antibodi
wv
nonfat
dri
milk
tbst
hr
room
temperatur
antirabbit
antimous
igghrp
conjug
antibodi
sheep
ge
healthcar
protein
visual
use
ecl
supersign
west
femto
chemiluminesc
reagent
pierc
detect
autoradiographi
follow
primari
sarscov
wt
black
blue
moi
describ
point
line
graph
repres
group
mean
error
bar
repres
sd
two
tail
student
ttest
use
determin
pvalu
c
cell
protein
lysat
ifn
treat
untreat
cell
probe
hour
post
infect
use
western
blot
rabbit
polyclon
antisar
n
antibodi
actin
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
infect
induc
phosphoryl
isg
product
vero
cell
protein
lysat
ifni
treat
untreat
cell
probe
hour
post
infect
western
blot
phosphoryl
actin
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
viral
protein
sequenc
ident
extract
align
viral
protein
heat
map
percent
sequenc
ident
construct
use
evolview
wwwevolgeniusinfoevolview
sarscov
refer
sequenc
tr
truncat
protein
ccbync
intern
licens
authorfund
made
avail
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
